BRPI0917245A2 - composto, uso de um composto, métodos para determinar a ocupação de ligação de um ligante de nk3 no receptor de nk3 em um animal, e para tratar uma doença, e, composiçãao farmacêutica - Google Patents
composto, uso de um composto, métodos para determinar a ocupação de ligação de um ligante de nk3 no receptor de nk3 em um animal, e para tratar uma doença, e, composiçãao farmacêuticaInfo
- Publication number
- BRPI0917245A2 BRPI0917245A2 BRPI0917245A BRPI0917245A BRPI0917245A2 BR PI0917245 A2 BRPI0917245 A2 BR PI0917245A2 BR PI0917245 A BRPI0917245 A BR PI0917245A BR PI0917245 A BRPI0917245 A BR PI0917245A BR PI0917245 A2 BRPI0917245 A2 BR PI0917245A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- occupation
- ligand
- receptor
- animal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 title 1
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801290 | 2008-09-15 | ||
| DKPA200801290 | 2008-09-15 | ||
| DKPA200900010 | 2009-01-06 | ||
| DKPA200900010 | 2009-01-06 | ||
| PCT/DK2009/050237 WO2010028655A1 (en) | 2008-09-15 | 2009-09-11 | Isoquinolinone derivatives as nk3 antagonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0917245A2 true BRPI0917245A2 (pt) | 2015-11-10 |
| BRPI0917245A8 BRPI0917245A8 (pt) | 2018-08-14 |
| BRPI0917245B1 BRPI0917245B1 (pt) | 2020-07-28 |
| BRPI0917245B8 BRPI0917245B8 (pt) | 2021-05-25 |
Family
ID=41227186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0917245A BRPI0917245B8 (pt) | 2008-09-15 | 2009-09-11 | compostos derivados de isoquinolinona e sua composição farmacêutica |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP2342182B1 (pt) |
| JP (1) | JP5536776B2 (pt) |
| KR (1) | KR101638641B1 (pt) |
| CN (1) | CN102149685B (pt) |
| AR (1) | AR073511A1 (pt) |
| AU (1) | AU2009291309B2 (pt) |
| BR (1) | BRPI0917245B8 (pt) |
| CA (1) | CA2732612C (pt) |
| CL (1) | CL2011000533A1 (pt) |
| CO (1) | CO6351781A2 (pt) |
| CY (1) | CY1113743T1 (pt) |
| DK (1) | DK2342182T3 (pt) |
| EA (1) | EA021581B1 (pt) |
| ES (1) | ES2399177T3 (pt) |
| HR (1) | HRP20130038T1 (pt) |
| IL (1) | IL210236A (pt) |
| MX (1) | MX2011001786A (pt) |
| MY (1) | MY164998A (pt) |
| NZ (1) | NZ591265A (pt) |
| PL (1) | PL2342182T3 (pt) |
| PT (1) | PT2342182E (pt) |
| RS (1) | RS52674B (pt) |
| SI (1) | SI2342182T1 (pt) |
| SM (1) | SMT201300020B (pt) |
| TW (1) | TWI454461B (pt) |
| WO (1) | WO2010028655A1 (pt) |
| ZA (1) | ZA201103119B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
| EA201170074A1 (ru) | 2008-06-23 | 2011-10-31 | Х. Лундбекк А/С | Изохинолиноновые производные в качестве антагонистов nk3 |
| TW201016688A (en) | 2008-10-20 | 2010-05-01 | Lundbeck & Co As H | Isoquinolinone derivatives as NK3 antagonists |
| TW201143768A (en) | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
| TW201144311A (en) * | 2010-03-12 | 2011-12-16 | Lundbeck & Co As H | Azaisoquionolinone derivatives as NK3 antagonists |
| SG11201402134VA (en) | 2011-11-09 | 2014-06-27 | Abbvie Deutschland | Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a |
| JP2021522341A (ja) * | 2018-04-27 | 2021-08-30 | ソージャニックス, インコーポレイテッド | イソキノリノンの多形及びアモルファス形態ならびにその使用方法 |
| US20250145574A1 (en) * | 2022-02-10 | 2025-05-08 | Carna Biosciences, Inc. | Fluoroisoquinoline compound and production method thereof |
| CN116621755A (zh) * | 2023-05-29 | 2023-08-22 | 山东玉满坤生物科技有限公司 | 一种吡拉西坦有关物质的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9825554D0 (en) * | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
| DE60209362T2 (de) * | 2001-04-11 | 2006-10-26 | Glaxosmithkline S.P.A. | 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten |
| GB0509405D0 (en) * | 2005-05-10 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| WO2008131779A1 (en) * | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
-
2009
- 2009-09-11 WO PCT/DK2009/050237 patent/WO2010028655A1/en not_active Ceased
- 2009-09-11 DK DK09776285.0T patent/DK2342182T3/da active
- 2009-09-11 CA CA2732612A patent/CA2732612C/en not_active Expired - Fee Related
- 2009-09-11 RS RS20130036A patent/RS52674B/sr unknown
- 2009-09-11 SI SI200930492T patent/SI2342182T1/sl unknown
- 2009-09-11 EA EA201170447A patent/EA021581B1/ru not_active IP Right Cessation
- 2009-09-11 JP JP2011526372A patent/JP5536776B2/ja not_active Expired - Fee Related
- 2009-09-11 MX MX2011001786A patent/MX2011001786A/es active IP Right Grant
- 2009-09-11 MY MYPI2011001144A patent/MY164998A/en unknown
- 2009-09-11 PL PL09776285T patent/PL2342182T3/pl unknown
- 2009-09-11 BR BRPI0917245A patent/BRPI0917245B8/pt not_active IP Right Cessation
- 2009-09-11 CN CN200980136727.XA patent/CN102149685B/zh not_active Expired - Fee Related
- 2009-09-11 HR HRP20130038AT patent/HRP20130038T1/hr unknown
- 2009-09-11 PT PT97762850T patent/PT2342182E/pt unknown
- 2009-09-11 KR KR1020117005880A patent/KR101638641B1/ko not_active Expired - Fee Related
- 2009-09-11 EP EP09776285A patent/EP2342182B1/en active Active
- 2009-09-11 ES ES09776285T patent/ES2399177T3/es active Active
- 2009-09-11 NZ NZ591265A patent/NZ591265A/xx not_active IP Right Cessation
- 2009-09-11 AU AU2009291309A patent/AU2009291309B2/en not_active Ceased
- 2009-09-14 TW TW098130900A patent/TWI454461B/zh not_active IP Right Cessation
- 2009-09-14 AR ARP090103522A patent/AR073511A1/es active IP Right Grant
-
2010
- 2010-12-23 IL IL210236A patent/IL210236A/en active IP Right Grant
-
2011
- 2011-03-04 CO CO11026657A patent/CO6351781A2/es not_active Application Discontinuation
- 2011-03-14 CL CL2011000533A patent/CL2011000533A1/es unknown
- 2011-04-28 ZA ZA2011/03119A patent/ZA201103119B/en unknown
-
2013
- 2013-02-06 CY CY20131100105T patent/CY1113743T1/el unknown
- 2013-02-13 SM SM201300020T patent/SMT201300020B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0917245A2 (pt) | composto, uso de um composto, métodos para determinar a ocupação de ligação de um ligante de nk3 no receptor de nk3 em um animal, e para tratar uma doença, e, composiçãao farmacêutica | |
| LTPA2018017I1 (lt) | Žmogaus CGRP receptorių rišantys antikūnai | |
| BRPI0814503A2 (pt) | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica | |
| BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
| BRPI0814688A2 (pt) | composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
| BRPI0819755A2 (pt) | composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória | |
| PT2170959E (pt) | Anticorpos para o receptor humano de morte programada pd-1 | |
| DK2242771T3 (da) | Bindingsmolekyler til den humane ox40-receptor | |
| BRPI0910656A2 (pt) | ´´compostos ligantes de receptor de estrogênio, uso dos mesmos e composição farmacéutica´´ | |
| BRPI0914007A2 (pt) | anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos | |
| BRPI0822398A2 (pt) | Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer | |
| BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
| BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BR112012016398A2 (pt) | Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa | |
| BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
| BRPI0821274A2 (pt) | composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
| BRPI0922233A2 (pt) | compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. | |
| BRPI0912348A2 (pt) | composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças | |
| IS8842A (is) | Kjarnviðtaka bindimiðlar. | |
| BRPI0903891A2 (pt) | Aparelho para estimativa de quantidade de acúmulo em dpf. | |
| BRPI0911297A2 (pt) | composição e métodos para preparo e uso das mesmas | |
| BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0907230A2 (pt) | composto, prodroga do composto, fármaco, método para tratar ou prevenir uma doença associada com as funções de um receptor de crf, e, uso do composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: SOJOURNIX, INC. (US) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2687 DE 05-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |